


REMARKS

This divisional application is directed to the invention of claims 23, 31 and 47 which correspond to their counterpart non-elected claims from the grandparent application serial number 09/713,449 filed November 18, 2000, now Patent No. 6,525,038 (which issued on February 25, 2003) and from the pending parent application serial number 10/371,088. Claims 23, 31 and 47 have herein been cancelled and replaced with claims 54-56 which cover the combination of Diflunisal (which is 5-(2,4-difluorophenyl)salicylic acid) and 2,4,6-trihydroxybenzoic acid(4,6-dihydroxysalicylic acid) and a method of treating cancer sensitive to this combination. New claims 57-58 depend from claim 56.

Applicant is substituting the attached replacement paragraph for the first full paragraph of page 1 of the specification in order to identify the relationship of this application to its immediate predecessors.

It is respectfully requested therefore that this Divisional application proceed to prosecution on the merits.

Respectfully submitted,


Eugene Lieberstein
Reg. No. 24,645

ANDERSON, KILL & OLICK
1251 Avenue of the Americas
New York, New York 10020-1182
(212) 278-1000

MAILING CERTIFICATE

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail in an envelope addressed: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, MAIL STOP PATENT APPLICATIONS (DIV.) on November 7, 2003 with label no. EU483331499US.



Date: November 7, 2003